Seres Therapeutics, Inc. - 8-K Filing
Seres Therapeutics stockholders approved an increase of 900,000 shares under the 2025 Incentive Award Plan on July 8, 2026. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 of this Current Report on Form 8-K (this “Current Report”), on July 8, 2026, Seres Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MCRB